Metrics to compare | COEGIN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOEGINPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.4x | −2.8x | −0.4x | |
PEG Ratio | −0.19 | −0.07 | 0.00 | |
Price/Book | 7.2x | 2.5x | 2.6x | |
Price / LTM Sales | 232.0x | 22.3x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 47.9% | |
Fair Value Upside | Unlock | −12.0% | 6.3% | Unlock |
Coegin Pharma AB, a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals. The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma. Coegin Pharma AB was founded in 2005 and is headquartered in Lund, Sweden.